Results 201 to 210 of about 726,579 (340)

Metformin suppresses intestinal polyp growth in ApcMin/+ mice

open access: yesCancer Science, 2008
A. Tomimoto   +10 more
semanticscholar   +1 more source

Five‐Year Experience of Nationwide Implementation of Colorectal Cancer Screening in Sweden

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 1, February 2026.
ABSTRACT Background Colorectal cancer (CRC) is a major health concern. In Sweden, a CRC screening program was implemented nationwide between 2019 and 2022. This study evaluated participation, colonoscopy adherence, and diagnostic outcomes for the program's first five years. Methods The target group of screening was all residents 60–74 years old.
Jóhann P. Hreinsson   +12 more
wiley   +1 more source

Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2005
N. Niho   +5 more
semanticscholar   +1 more source

Severe anaemia secondary to duodenal adenoma in a cat

open access: yesVeterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract A 7‐year‐old female, spayed, domestic shorthair presented with a 24‐hour history of anorexia, lethargy and melaena. The cat was hospitalized and received treatment for hypovolemia, various electrolyte abnormalities and severe anaemia with a blood transfusion, intravenous fluids and medications.
Jocosa Yasenchack   +4 more
wiley   +1 more source

ADULT LIPOMATOUS POLYP INTESTINAL INTUSSUSCEPTION : A RARE ENTITY

open access: diamond, 2015
Neeraj Kumar Banoria   +2 more
openalex   +1 more source

Dose‐dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPARγ ligand

open access: yesCancer Science, 2003
N. Niho   +6 more
semanticscholar   +1 more source

Impact of Prior Intravenous Immunoglobulin and Plasmapheresis on Eculizumab or Ravulizumab Treatment for Generalized Myasthenia Gravis: An Analysis of the MG SPOTLIGHT Registry

open access: yesClinical and Experimental Neuroimmunology, Volume 17, Issue 1, February 2026.
ABSTRACT Objective The complement component 5 inhibitor therapies (C5ITs) eculizumab and ravulizumab are approved for the treatment of generalized myasthenia gravis (gMG). We evaluated the real‐world effectiveness and safety of eculizumab and ravulizumab in patients with gMG with or without prior intravenous immunoglobulin (IVIg) or plasma exchange ...
Akiyuki Uzawa   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy